Efficacy and Safety of Once-daily Boosted Darunavir (Prezista) versus Lopinavir/ritonavir (Kaletra) in Treatment-naive HIV Patients: ARTEMIS Trial - 7/15/08

Double-boosted Protease Inhibitors Saquinavir (Invirase) and Lopinavir/ritonavir (Kaletra) Produce Significant CD4 Rise and Viral Load Decline in Treatment-experienced Children - 6/10/08

Lower-Strength Lopinavir/Ritonavir (Kaletra, Aluvia) Tablet Approved in Europe for Children with HIV  - 4/11/08

Is There a Potential Role for Ritonavir-boosted Protease Inhibitor Monotherapy? - 4/01/08

Once-daily Lopinavir/ritonavir (Kaletra) and Nevirapine (Viramune) Appear as Effective as Twice-daily - 2/22/08

Double Protease Inhibitor Therapy with Lopinavir/ritonavir (Kaletra) plus Atazanavir (Reyataz) in Treatment-naive Patients: LORAN Study - 2/15/08

Bone Mineral Density (BMD) 96 Weeks after Antiretroviral Therapy (ART) Initiation: A Randomized Trial Comparing Efavirenz (EFV)-Based Therapy to a Lopinavir/ ritonavir (LPV/r)-Containing Regimen with Simplification to LPV/r Monotherapy.   - 2/10/08

Study M05-730 Primary Efficacy Results at Week 48: Phase 3, Randomized, Open-Label Study of Lopinavir/ritonavir (LPV/r) Tablets Once Daily (QD) versus Twice Daily (BID), Co-Administered with Tenofovir DF (TDF) + Emtricitabine (FTC) in Antiretroviral-Naïve (ARV) HIV-1 Infected Subjects.   - 2/10/08

Prevalence, Mutational Patterns and Phenotypic Correlates of the L76V Protease Mutation in Relation to LPV Associated Mutations.   - 2/10/08

Lopinavir/ritonavir (LPV/r) 500/125 mg BID Plus Efavirenz Approximate the Pharmacokinetic Exposure of LPV/r 400/100 mg BID Administered Alone in Healthy Adult Subjects.   - 2/10/08

Impact of a 48-week Lopinavir/r Monotherapy on HIV1-DNA in Blood Cells in the MONARK Trial.   - 2/10/08

Efficacy and Safety of Abacavir/Lamivudine Compared to Tenofovir/Emtricitabine in Combination with Once-Daily Lopinavir/Ritonavir through 48 Weeks in the HEAT Study   - 2/10/08

Boosted Atazanavir (Reyataz) and Lopinavir/ritonavir (Kaletra) Have Similar Efficacy, but Different Side Effects: CASTLE Study - 2/05/08

Inferior Long-term Efficacy of Lopinavir/ritonavir (Kaletra) Monotherapy - 1/25/08

Use of Lopinavir/ritonavir (Kaletra) in Infants Less than 6 Months of Age - 1/08/08

Cost Effectiveness of Lopinavir/ritonavir (Kaletra) vs Atazanavir/ritonavir (Reyataz) in Treatment-experienced HIV Patients - 11/27/07

U.S. FDA Approves New Lower-dose Formulation of Lopinavir/ritonavir (Kaletra) for Children - 11/16/07

Lopinavir/ritonavir (Kaletra) Monotherapy Is Effective for Some Patients, but Once-daily Dosing Can be Risky without Optimal Adherence - 11/06/07

Lopinavir/ritonavir monotherapy versus lopinavir/ritonavir and two nucleosides for maintenance therapy of HIV. Ninety-six week results of a randomized, controlled, open-label clinical trial (OK04 Study) - 11/06/07

Achieving and Maintaining Undetectable HIV-1 RNA: The Role of Adherence - 11/06/07

Switching from Lopinavir/Ritonavir (LPV/r) Soft Gel Capsule (SGC) to Tablet Formulation improves Tolerability in Indigent AIDS Clinic - 11/06/07

Prognostic Factors of Virological Success in Antiretroviral-naïve Patients Receiving LPV Monotherapy in the MONARK trial - 11/06/07

Predictors of Persistence With Lopinavir/ritonavir (LPV/r) Soft-Gelatin Capsule-Based Antiretroviral Regimens - 11/06/07

Beneficial Effects of a Switch to a Lopinavir/rit (LPV/r)-Containing Regimen for Patients With Partial or No Immune Reconstitution With HAART Despite Complete Viral Suppression - 11/06/07

Lopinavir/Ritonavir (LPV/r) 100/25 mg Tablet Developed for Pediatric Use: Bioequivalence to the LPV/r 200/50 mg Tablet at a Dose of 400/100 mg and Predicted Dosing Regimens in Children - 11/06/07

Safety of Kaletra as Initial Therapy: A Combined Analysis of Phase II and III Clinical Trials - 11/06/07

CD4+ T-cell Response to Lopinavir/ritonavir-based Therapy in Antiretroviral-naïve HIV-1 Infected Subjects: The Role of Adherence - 11/06/07

Single Agent Therapy (SAT) with Lopinavir/ritonavir (LPV/r) Controls HIV-1 Viral Replication in the Female Genital Tract - 11/06/07

Comparing the cost-effectiveness of first-line HAART regimens - 11/06/07

The Role of Adherence in Immunological Response to Lopinavir/ritonavir (Kaletra) Regimens in Treatment-naive HIV Patients - 11/06/07

Lopinavir/ritonavir (Kaletra) Monotherapy Is Effective for Some Patients, but Once-daily Dosing Can be Risky without Optimal Adherence - 11/06/07

Lopinavir/ritonavir (Kaletra) Significantly Reduces the HIV RNA Level in Cerebrospinal Fluid - 10/23/07

Efficacy and Safety of Ritonavir-boosted Saquinavir (Invirase) Versus Lopinavir/ritonavir (Kaletra): Final 48-week Results of the Gemini Study - 10/30/07

The Role of Adherence in Immunological Response to Lopinavir/ritonavir (Kaletra) Regimens in Treatment-naive HIV Patients - 10/26/07

Lopinavir/ritonavir (Kaletra) Significantly Reduces the HIV RNA Level in Cerebrospinal Fluid - 10/23/07

High-dose Lopinavir/ritonavir (Kaletra) Significantly Improves Response to Therapy without Increasing Adverse Events in Highly Treatment-experienced HIV Patients - 8/31/07